MIRM News and Press, Mirum Pharmaceuticals Inc. From 10/14/22

- CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with Alagille syndrome (ALGS). - Following CHMP recommendation, a decision by the Eur...

- Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome (ALGS) - Characterization of four-year growth improvement in Alagille syndrome with maralixibat - New analysis evaluating health-related...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present three posters and host a scientific symposium during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place October 12-16, 2022, in Orlando...

Following the public offering, Mirum is in an excellent financial position to accelerate both the Livmarli launch and the clinical development pipeline. The biggest value driver is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the closing of its previously announced underwritten public...

WM Technology ( MAPS ) -30% on Q2 earnings release . Sweetgreen ( SG ) -22% on Q2 earnings release . Rackspace Technology ( RXT ) -20% on Q2 earnings release . BigBear.ai Holdings ( BBAI ) -20% on Q2 earnings release . PLBY G...

Mirum Pharmaceuticals ( NASDAQ: MIRM ) falls 10.9% after-hours Tuesday on pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share for expected gross proceeds of $80.0M. Un...

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2022 Earnings Conference Call August 04, 2022, 04:30 PM ET Company Participants Ian Clements - CFO Chris Peetz - President and CEO Peter Radovich - COO Pam Vig - Head, R&D Conference Call Participants Jess...

- Net product sales for LIVMARLI ® (maralixibat) oral solution totaled $17.5 million in the second quarter of 2022 and $28.4 million year-to-date - Conference call to provide business updates today, August 4 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022. That same day, Mirum will host a conference call to discuss the company’s progress and priorities for 2022. Conference call details: ...